Holen Sie sich die Stockscreener-App
42.97
1.44%
0.61
Handel nachbörslich:
43.01
0.04
+0.09%
Schlusskurs vom Vortag:
$42.36
Offen:
$42.32
24-Stunden-Volumen:
3.39M
Relative Volume:
0.86
Marktkapitalisierung:
$18.36B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$1.30B
KGV:
24.57
EPS:
1.7487
Netto-Cashflow:
$1.05B
1W Leistung:
+5.47%
1M Leistung:
+10.58%
6M Leistung:
+15.79%
1J Leistung:
+37.15%
1-Tages-Spanne:
$42.28
$43.07
1-Wochen-Bereich:
$40.16
$43.07
52-Wochen-Spanne:
$29.66
$43.07
Royalty Pharma Plc Stock (RPRX) Company Profile
Firmenname
Royalty Pharma Plc
Sektor
Branche
Telefon
(212) 883-0200
Adresse
110 EAST 59TH STREET, NEW YORK, NY
Vergleichen Sie RPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
42.97 | 18.10B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.61 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.18 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
851.72 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.80 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.38 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | UBS | Neutral → Buy |
| 2025-09-30 | Eingeleitet | Goldman | Buy |
| 2025-05-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-06-03 | Herabstufung | UBS | Buy → Neutral |
| 2022-06-14 | Fortgesetzt | UBS | Buy |
| 2022-05-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2022-04-14 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-07-30 | Eingeleitet | Tigress Financial | Buy |
| 2020-11-09 | Hochstufung | UBS | Neutral → Buy |
| 2020-07-14 | Eingeleitet | Evercore ISI | In-line |
| 2020-07-13 | Eingeleitet | BofA Securities | Buy |
| 2020-07-13 | Eingeleitet | Citigroup | Neutral |
| 2020-07-13 | Eingeleitet | Cowen | Outperform |
| 2020-07-13 | Eingeleitet | Goldman | Neutral |
| 2020-07-13 | Eingeleitet | JP Morgan | Neutral |
| 2020-07-13 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Eingeleitet | SunTrust | Buy |
| 2020-07-13 | Eingeleitet | UBS | Neutral |
Alle ansehen
Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten
Urist Marshall, royalty pharma EVP, sells $821,810 in shares - Investing.com
Royalty Pharma (RPRX) Stock Analysis: Analysts See 15% Upside Potential - DirectorsTalk Interviews
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 31,045 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Strs Ohio Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma stock hits 52-week high at $41.71 By Investing.com - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma stock hits 52-week high at $41.71 - Investing.com
Royalty Pharma Shares Rise After UBS Upgrade - marketscreener.com
UBS Upgrades Royalty Pharma to Buy From Neutral, Adjusts Price Target to $49 From $38 - marketscreener.com
Ruffer LLP Decreases Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Assessing Royalty Pharma (RPRX) Valuation After Teva Autoimmune Funding Partnership Attracts Fresh Attention - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock - MarketBeat
Royalty Pharma PLC $RPRX Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Mitsubishi UFJ Trust & Banking Corp Sells 198,889 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cullen Frost Bankers Inc. Raises Position in Royalty Pharma PLC $RPRX - MarketBeat
(RPRX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Jim Cramer on Royalty Pharma: "It's a Terrific Company" - Finviz
84,741 Shares in Royalty Pharma PLC $RPRX Bought by Oxbow Advisors LLC - MarketBeat
Jim Cramer on Royalty Pharma: “It’s a Terrific Company” - Insider Monkey
Jim Cramer Shared His Takes on These 16 Stocks - Insider Monkey
Baillie Gifford & Co. Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells shares worth $2.7 million By Investing.com - Investing.com Nigeria
Royalty Pharma EVP Coyne sells shares worth $2.7 million - Investing.com
Terrance Coyne Sells 69,582 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Smart Money: Is UAMY stock a buy or sellGDP Growth & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's - simplywall.st
How Investors May Respond To Royalty Pharma (RPRX) Dividend Hike Amid Insider Sales And Results Countdown - Yahoo Finance
Royalty Pharma (RPRX) Valuation Check After Recent Share Pullback And Strong 1 Year Return - Yahoo Finance
Patient Capital Management LLC Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Dividend Hike Highlights Income Appeal And Undervaluation - Sahm
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells $790,400.00 in Stock - MarketBeat
Royalty Pharma to announce fourth quarter and full year 2025 financial results on February 11, 2026 - marketscreener.com
Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - The Globe and Mail
Royalty Pharma plc to Release Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026 - Quiver Quantitative
Sumitomo Mitsui Trust Group Inc. Buys 207,338 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Nordea Investment Management AB Acquires 120,004 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Latham Watkins Advises on Royalty Financing Agreement Between Teva and Royalty Pharma - Latham & Watkins LLP
Royalty Pharma announces planned legal leadership transition - MSN
Eastern Bank Boosts Stake in Royalty Pharma PLC $RPRX - MarketBeat
Urist Marshall, evp at Royalty Pharma, sells $815k in shares - Investing.com Nigeria
Aug Technicals: Will Royalty Pharma plc stock remain a Wall Street favoriteDollar Strength & High Win Rate Trade Alerts - moha.gov.vn
Urist Marshall, evp at Royalty Pharma, sells $815k in shares By Investing.com - Investing.com Canada
Royalty Pharma Insider Sold Shares Worth $815,634, According to a Recent SEC Filing - marketscreener.com
Liquidity Mapping Around (RPRX) Price Events - Stock Traders Daily
Will Royalty Pharma plc stock remain a Wall Street favoriteNew Guidance & Safe Entry Trade Signal Reports - Bộ Nội Vụ
Royalty pharma reports record year for royalty funding market By Investing.com - Investing.com Nigeria
Royalty Pharma promises $500M to Teva for advancing vitiligo treatment - MSN
Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Royalty Pharma Plc-Aktie (RPRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Urist Marshall | EVP, Research & Investments |
Jan 30 '26 |
Sale |
41.09 |
20,000 |
821,810 |
0 |
| Urist Marshall | EVP, Research & Investments |
Jan 23 '26 |
Sale |
40.26 |
20,000 |
805,110 |
20,000 |
| Coyne Terrance P. | EVP & CFO |
Jan 20 '26 |
Sale |
39.35 |
69,582 |
2,737,940 |
36,010 |
| Urist Marshall | EVP, Research & Investments |
Jan 16 '26 |
Sale |
39.52 |
20,000 |
790,346 |
40,000 |
1.22%
2.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):